IMHOTEP phase II trial of neoadjuvant pembrolizumab in dMMR/MSI localized cancers: Results of the digestive non-colorectal cancer cohorts

被引：0
|
作者：
de la Fouchardiere, C. [1 ]
Zaanan, A. [2 ]
Cohen, R. [3 ]
Le Sourd, S. M. [4 ]
Tougeron, D. [5 ]
Soularue, E. [6 ]
Dubreuil, O. [7 ]
Williet, N. [8 ]
Samalin-Scalzi, E. [9 ]
Piessen, G. [10 ]
Hautefeuille, V. [11 ]
Jary, M. [12 ]
Ben Abdelghani, M. [13 ]
Evesque, L. [14 ]
Rochigneux, P. [15 ]
Blanc, E. [16 ]
Bibeau, F. [17 ]
DeMontfort, A. [18 ]
Coutzac, C. [19 ]
机构：
[1] Ctr Leon Berard, Med Oncol, Lyon, France
[2] Hop Europeen Georges Pompidou, AP HP, Digest Oncol, Paris, France
[3] Hop St Antoine, Med Oncol, Paris, France
[4] Ctr Eugene Marquis, Digest Oncol, Rennes, France
[5] CHU Poitiers, Jean Bernard Hop, Gastroenterol & Digest Oncol, Poitiers, France
[6] Inst Mutualiste Montsouris, Med Oncol, Paris, France
[7] Gh Diaconesses Croix St Simon, Med Oncol, Paris, France
[8] Hop Nord St Priest Jarez, Gastroenterol & Digest Oncol, St Priest En Jarez, France
[9] ICM Inst Canc Montpellier, Med Oncol, Montpellier, France
[10] CHU Claude Huriez, Digest Surg, Lille, France
[11] CHU Amiens Picardie, Gastroenterol & Digest Oncol, Amiens, France
[12] CHU Clermont Ferrand Site Estaing, Med Oncol, Clermont Ferrand, France
[13] ICANS Inst Cancerol Strasbourg Europe, Med Oncol, Strasbourg, France
[14] Ctr Anticancer Antoine Lacassagne, GI Oncol, Nice, France
[15] IPC Inst Paoli Calmettes, Med Oncol, Marseille, France
[16] Ctr Leon Berard, Clin Res, Lyon, France
[17] CHU Besancon, Pathol, Besancon, France
[18] Ctr Leon Berard, Biostat, Lyon, France
[19] Ctr Leon Berard, Digest Oncol, Lyon, France
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.1514
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1448P
引用
收藏
页码：S899 / S900
页数：2
相关论文
共 50 条
  • [21] PEMREC: A phase II study to evaluate safety and efficacy of neoadjuvant pembrolizumab and radiotherapy in localized microsatellite stable rectal cancer
    Kossler, T.
    Buchs, N.
    Dutoit, V.
    Puppa, G.
    Tsantoulis, P.
    Frossard, J.
    Bichard, P.
    McKee, T.
    Di Marco, M.
    Dietrich, P.
    Roth, A.
    Zilli, T.
    Ris, F.
    ANNALS OF ONCOLOGY, 2020, 31 : S127 - S127
  • [22] Pembrolizumab in microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) advanced solid tumors: An update of the phase II KEYNOTE-158 trial
    Maio, M.
    Ascierto, P. A.
    Motola Kuba, D.
    Penel, N.
    Cassier, P. A.
    Bariani, G. M.
    De Jesus-Acosta, A.
    Doi, T.
    Longo Munoz, F.
    Miller, W. H.
    Oh, D-Y.
    Gottfried, M.
    Yao, L.
    Jin, F. J.
    Gozman, A.
    Marabelle, A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S589 - S590
  • [23] Exemestane as neoadjuvant hormonotherapy for locally advanced breast cancer: Results of a phase II trial
    Tubiana-Hulin, Michele
    Becette, Veronique
    Bieche, Ivan
    Mauriac, Louis
    Romieu, Gilles
    Bibeau, Frederic
    MacGrogan, Gaetan
    Bourgeois, Hugues
    Chollet, Philippe
    Defrance, Remy
    Spyratos, Frederique
    ANTICANCER RESEARCH, 2007, 27 (4C) : 2689 - 2696
  • [24] Randomized phase II trial of neoadjuvant everolimus in patients with high-risk localized prostate cancer
    Koshkin, Vadim S.
    Mir, Maria C.
    Barata, Pedro
    Gul, Anita
    Gupta, Ruby
    Stephenson, Andrew J.
    Kaouk, Jihad
    Berglund, Ryan
    Magi-Galluzzi, Cristina
    Klein, Eric A.
    Dreicer, Robert
    Garcia, Jorge A.
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (03) : 559 - 566
  • [25] Phase II clinical trial of subtype directed neoadjuvant therapy in patients with localized pancreatic cancer.
    Tsai, Susan
    Borazanci, Erkut
    Gulley, Margaret
    Rashid, Naim
    Merker, Jason
    Khan, Abdul H.
    Chisholm, Phillip
    Hunt, Bryan
    Giorgadze, Tamara
    Hall, William
    Kamgar, Mandana
    Evans, Douglas B.
    Yeh, Jen Jen
    CANCER RESEARCH, 2021, 81 (22) : 38 - 39
  • [26] Randomized phase II trial of neoadjuvant everolimus in patients with high-risk localized prostate cancer
    Vadim S. Koshkin
    Maria C. Mir
    Pedro Barata
    Anita Gul
    Ruby Gupta
    Andrew J. Stephenson
    Jihad Kaouk
    Ryan Berglund
    Cristina Magi-Galluzzi
    Eric A. Klein
    Robert Dreicer
    Jorge A. Garcia
    Investigational New Drugs, 2019, 37 : 559 - 566
  • [27] Multicenter Phase I/II Trial of Napabucasin and Pembrolizumab in Patients with Metastatic Colorectal Cancer (EPOC1503/SCOOP Trial)
    Kawazoe, Akihito
    Kuboki, Yasutoshi
    Shinozaki, Eiji
    Hara, Hiroki
    Nishina, Tomohiro
    Komatsu, Yoshito
    Yuki, Satoshi
    Wakabayashi, Masashi
    Nomura, Shogo
    Sato, Akihiro
    Kuwata, Takeshi
    Kawazu, Masahito
    Mano, Hiroyuki
    Togashi, Yosuke
    Nishikawa, Hiroyoshi
    Yoshino, Takayuki
    CLINICAL CANCER RESEARCH, 2020, 26 (22) : 5887 - 5894
  • [28] Phase II trial of neoadjuvant exemestane [EXE] and celecoxib [CELE] in breast cancer: Results of biomarkers
    Shapiro, C. L.
    Povoski, S. P.
    Jiminez, R.
    Dehart, J.
    Ottman, S.
    Shiels, D. R.
    Xiaobia, L.
    Brueggemeier, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [29] Results of a Multicenter Randomized Phase II Trial of Resection ± Neoadjuvant Chemoradiation Therapy in Pancreatic Cancer
    Brunner, T.
    Golcher, H.
    Witzigmann, H.
    Marti, L.
    Bechstein, W. O.
    Bruns, C.
    Hauss, J. P.
    Merkel, S.
    Fietkau, R.
    Hohenberger, W.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S90 - S91
  • [30] Neoadjuvant atezolizumab (A) for resectable non-small cell lung cancer (NSCLC): Results from the phase II PRINCEPS trial
    Besse, B.
    Adam, J.
    Cozic, N.
    Chaput-Gras, N.
    Planchard, D.
    Mezquita, L.
    Remon Masip, J.
    Lavaud, P.
    Naltet, C.
    Gazzah, A.
    de Montpreville, V. Thomas
    Ghigna, M. -R.
    Mussot, S.
    Fadel, E.
    Mabille, L.
    Duchemann, B.
    Barlesi, F.
    Soria, J-C.
    Caramella, C.
    Mercier, O.
    ANNALS OF ONCOLOGY, 2020, 31 : S794 - S795
12345